Other Diseases
Aquestive maps out FDA approval for sublingual anaphylaxis drug
Aquestive Therapeutics has revealed topline data from the Phase III pharmacokinetic (PK) study of its anaphylactic drug, Anaphylm (epinephrine) sublingual…
J&J touts success of nipocalimab in two rare disease trials
Johnson & Johnson (J&J) has announced positive topline results for nipocalimab in two rare disease indications - generalised myasthenia gravis…
EASD 2023: meta-analysis shows tirzepatide superiority to semaglutide
At the 59th Annual European Association for the Study of Diabetes (EASD) 2023 meeting, a new meta-analysis has shown the…
Kashiv completes Phase I trial for Xolair biosimilar
US-based Kashiv Biosciences has successfully completed a Phase I trial for its Xolair biosimilar ADL018, the company’s latest biosimilar in…
FDA reviews protocol of NLS Pharmaceutics’ study of Mazindol ER
The US Food and Drug Administration (FDA) has reviewed the full protocol of NLS Pharmaceutics’ NLS-1031 study, which is part…
Chinook reports data from Phase I trial of CHK-336
Chinook Therapeutics has reported results from a Phase I trial evaluating CHK-336, an oral small molecule LDHA inhibitor, in development…
Mirum completes enrollment of Phase IIb trial for biliary atresia
Mirum has completed enrollment for its Phase IIb EMBARK study evaluating Livmarli (maralixibat) in infants with biliary atresia who have…
Omega-3 Fatty Acids May Reduce Risk of Chronic Kidney Disease
Chronic kidney disease (CKD) is a condition characterised by a gradual loss of kidney function over time, leading to the…
Pipeline Moves: Phase II cancer trial of Roche asset terminated, shot at further study drops
In this week’s Pipeline Moves, we start off with the termination of an investigator-led Phase II cancer study of Roche’s…
Failure for Servier and Neurochlore’s autism drug, but potential remains in market
On 7 September, Servier and Neurochlore announced that following a lack of efficacy of bumetanide for autism spectrum disorder (ASD)…